Business News (Licences, Deals)
Global Rights
06-03-2009 |
15:05 hs.
US Biotechnology Company Genzyme Corp. announced acquisition of Bayer AG global rights for multiple sclerosis drug Campath/MabCampath (Alemtuzumab) as well as worldwide rights for two cancer drugs.
06-01-2009 |
13:53 hs.
US-based Baxter International Inc. said they acquired 4.8 percent of British biologic drugs and vaccines developer, Lipoxen Plc.
12-30-2008 |
07:53 hs.
Novartis AG bought patent rights for AlphaVax Inc’s experimental vaccine to prevent cytomegalovirus infection in newborns, for an estimated upfront payment of $20 million dollars.
12-01-2008 |
16:21 hs.
U.S. biotechnology company Alkermes Inc said it regained rights for alcohol dependence treatment Vivitrol after Cephalon Inc ended a portfolio review. The drug is an extended-release version of the generic drug naltrexone.
11-17-2008 |
16:28 hs.
11-10-2008 |
10:29 hs.
Up to $307 M in milestone payments, plus royalties
11-07-2008 |
09:53 hs.
British biotechnology company BTG Plc announced it has granted worldwide rights to Onyx Pharmaceuticals, Inc. to develop BTG’s novel anticancer compound, BGC 945. BTG will receive an upfront payment of $13 M and has the potential to receive development milestone payments, plus royalties.
As much as $ 1.38 B dollar agreement
11-04-2008 |
11:07 hs.
Genzyme Corp. will pay Osiris Therapeutics Inc. as much as $ 1.38 billion dollars to develop two experimental drugs, Prochymal and Chondrogen, using adult stem cells.
Pushing for a sale
11-04-2008 |
09:40 hs.
Eastbourne Capital, since August a 12.5-percent shareholder in Amylin Pharmaceuticals Inc, said it intends to hold discussions on ways to improve shareholder value, including the possible sale of the biotechnology company, maker of diabetes drug Byetta.
Experimental oncology treatment GA101
10-31-2008 |
10:06 hs.
Biogen Idec and Genentech Inc announced they would be jointly developing an experimental cancer treatment that works through a similar mechanism as their shared blockbuster Rituxan/Mabthera treatment for non-Hodgkins lymphoma and rheumatoid arthritis. Genentech acquired the rights to GA101 from Roche Holding AG, a majority shareholder in Genentech.
10-16-2008 |
11:31 hs.
For skin cancer drug in Phase III
10-14-2008 |
12:09 hs.
Synta Pharmaceuticals Inc. reported it has received a $ 25 million dollar payment from U.K. drugmaker GlaxoSmithKline Plc after reaching a milestone under the companies´ development agreement for the cancer drug elesclomol.
Milestone payment
10-10-2008 |
12:06 hs.
09-29-2008 |
13:11 hs.
Reported by WSJ
09-29-2008 |
09:22 hs.
According to sources close to the company, it is possible ImClone Systems Inc may be reporting further news regarding its continuing talks to sell itself to a major pharmaceutical concern for a price in the range of $ 6.1 billion dollars. The news was published by the Wall Street Journal.
09-23-2008 |
08:32 hs.
Autoimmune, transplant rejection products
09-19-2008 |
12:03 hs.
Biotechnology company Maxygen Inc signed an agreement with Japan´s Astellas Pharma Inc to develop drugs for autoimmune diseases and transplant rejection, the companies announced. Maxygen will receive an initial $ 10 million dollars, and up to $ 160 million dollars in milestone payments. Further details.
09-19-2008 |
11:13 hs.
09-15-2008 |
08:46 hs.
Amgen Inc. announced signing a deal with Swedish firm Biovitrum AB, wherein Amgen will sell its biologic therapeutic products Kepivance and Stemgen to Biovitrum. In addition, Amgen will also sell to Biovitrum its worldwide exclusive license to Kineret for the currently approved indication. The financial terms of the transaction include an upfront payment of approximately $130 million.
Topping Bristol-Myers Squibb´s $ 60
09-10-2008 |
11:44 hs.
Biotechnology company ImClone Systems Inc reported it has received an offer from a large (undisclosed) pharmaceuticals company to buy ImClone for $ 70 dollars a share in cash, topping Bristol-Myers Squibb´s offer by 15 percent.
